

Date Mailed: March 10, 2005

BT19 Rec'd PCT/PTO

10 MAR 2005

Sheet 1 of 1

10/527761

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: 184.5USWO		Int'l Appln No.: PCT/GB03/003801
	Applicant: Alan Crossman et al.		Int'l Filing Date: 1 Sept 2003
	Filing Date: Herewith	Group Art Unit: To be assigned	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
/S.J./	WO00/61138	10/19/00	PCT				
/S.J./	WO02/064085	08/22/02	PCT				
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
/S.J./		Abuzzahab et al., "Control of Tourette's Syndrome with Topiramate", American Journal of Psychiatry, Vol. 158, No. 6, June 2001, pg. 968, XP009022623.					
/S.J./		Abuzzahab et al., "Topiramate for Clozapine-Induced Seizures", American Journal of Psychiatry, American Psychiatric Association, Washington, D.C., Vol. 158, No. 6, June 2001, pp. 968-969, XP001095768.					
/S.J./		Coppola et al., "Topiramate as Add-On Drug in Severe Myoclonic Epilepsy in Infancy: An Italian Multicenter Open Trial", Epilepsy Research, Vol. 49, No. 1, March 2002, pp. 45-48, XP002264038.					
/S.J./		Dursun et al., "Clozapine Weight Gain, Plus Topiramate Weight Loss", Canadian Journal of Psychiatry, Revue Canadienne de Psychiatrie, Canadian Psychiatric Association, Ottawa, CA, Vol. 45, No. 2, March 2000, pg. 198, XP001097327.					
/S.J./		Kellett et al., "Topiramate in Clinical Practice: First Year's Postlicensing Experience in a Specialist Epilepsy Clinic", Journal of Neurology Neurosurgery and Psychiatry, Vol. 66, No. 6, June 1999, pp. 759-763, XP002264039.					

EXAMINER: /Sahar Javanmard/	DATE CONSIDERED: 01/17/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

G&C 184.5-US-WO